Author:
Van Muijen Marloes E.,Thomas Sarah E.,Groenewoud Hans M.M.,Otero Marisol E.,Ossenkoppele Paul M.,Njoo Marcellus D.,Dodemont Sharon R.P.,Kop Else N.,Berends Maartje A.M.,Koetsier Marjolein I.A.,Mommers Johannes M.,Körver John E.M.,Tupker Ron A.,De Bruin-Weller Marjolein S.,Weppner-Parren Lizelotte J.M.T.,Peters Bas,Kleinpenning Marloes M.,Kuijpers Astrid L.A.,Arnold W. Peter,Van Lümig Paula P.M.,Van den Reek Juul M.P.A.,De Jong Elke M.G.J.
Abstract
Real-world evidence, directly comparing the effectiveness of interleukin (IL)17-inhibitors, IL23-inhibitors, tumour necrosis factor alpha (TNF-α)-inhibitors and an IL12/23-inhibitor in psoriasis, is scarce. The aim of this study was to directly compare the first-year effectiveness of biologic therapies for psoriasis, corrected for confounders. This prospective, multicentre cohort study assessed BioCAPTURE data on etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab in 1,080 treatment episodes of 700 patients with psoriasis. The course of the mean absolute Psoriasis Area and Severity Index (PASI) and the proportion of patients who achieved PASI90/PASI75 were compared using linear mixed models and mixed logistic regression models respectively, corrected for baseline PASI, biologic naivety, and weight. Patients treated with adalimumab, ustekinumab, secukinumab, ixekizumab, or guselkumab all had a significantly lower mean PASI after 12 months compared with etanercept, and significantly higher overall odds of reaching PASI90 than those treated with etanercept. Patients treated with ixekizumab or guselkumab also had higher probabilities of reaching PASI90 than adalimumab, ustekinumab, and secukinumab. Relative to randomized controlled trials, the proportions of patients who reached PASI90/75 were lower in this real-world study.
Publisher
Medical Journals Sweden AB
Subject
Dermatology,General Medicine
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献